Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 1/2 6Phase 2 4Phase NA 1

Status

Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × efineptakin alfa × Clear all
NCT05286060 2026-02-09

GENUINE

Yonsei University

Phase 2 Active not recruiting
56 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

NeoImmuneTech

Phase 2 Active not recruiting
83 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05191784 2023-06-12

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Genexine, Inc.

Phase 2 Unknown
20 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡